First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform

SmartCella Holding AB (“SmartCella”) today shares an update from XyloCor Therapeutics (”XyloCor”). XyloCor recently announced that the first patient has been dosed in their Phase IIb EXACT-2 trial, evaluating their XC001 therapy for patients with refractory angina using SmartCella’s Extroducer as the investigational delivery platform.

SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. SmartCella combines novel delivery platforms, such as the Extroducer®, with state-of-the-art development and manufacturing of cell therapies.

The Extroducer is an investigational, endovascular delivery platform with the ability to inject payload directly to otherwise hard-to-reach organs and tissues, such as the heart, the liver and the pancreas. It is designed to be a minimally invasive therapeutic delivery device to be used with diverse therapeutics including small molecules, biologics, and cell and gene therapies. Developed at Karolinska Institutet, it uses an inverted Seldinger technique for easy and precise access to target tissues, e.g. solid tumors, via blood vessels and is designed to enable injection of therapeutics in the right concentration at the right location to reduce the risks of side effects and achieve better effects.

XyloCor is a US-based private, clinical-stage biopharmaceutical company developing potential best-in-class gene therapies to transform outcomes for patients with cardiovascular disease. Their lead product candidate, XC001, is in clinical development for use in patients with coronary artery disease and refractory angina for whom there are no treatment options. SmartCella and XyloCor have been license partners since July 2024.

CEO Niklas Prager comments: “We are incredibly pleased with our collaboration with XyloCor and congratulate the team for achieving first patient dosing using the Extroducer delivery system for their XC001 therapy to treat refractory angina. Building on the very promising results from the Phase I/II EXACT-1 trial, this represents a significant milestone for both SmartCella and XyloCor and provides hope for patients with this debilitation disease. The potential to deliver advanced therapies with the Extroducer directly into the heart, tumors or other tissues, without invasive surgery is truly transformative for patients, clinicians and the healthcare system.”

Read the press release issued by XyloCor Therapeutics here.

Contact

Niklas Prager, CEO +46 76 811 77 44

Nina Nornholm, Head of Communication +46 708 550 356

About SmartCella

SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden. SmartCella combines novel delivery platforms, such as the Extroducer® (an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors), with cutting-edge development and manufacturing of cell therapies. The company has two operating segments: Targeted Delivery and Regenerative Medicines. The Extroducer has been FDA-cleared for use in peripheral tissues and is a clinical-stage investigational device for the heart.

The international team consists of scientists, visionary innovators, and experienced business leaders, all dedicated to shaping the future of targeted therapies and delivering life-changing treatments to patients.

Read more www.smartcella.com and follow SmartCella on LinkedIn